

CURRICULUM VITAE

Raquel Largo, PhD



Personal information:

Name: Raquel

Surname: Largo Carazo

Female

E-MAIL: rlargo@fjd.es / rlargocarazo@hotmail.com

Researcher's identification number:

Open Researcher and Contributor ID (ORCID): 0000-0001-6525-2944

Researcher ID: B-2949-2009

Scopus Author ID: 7005741188

Academic data:

- Chemistry degree at University Complutense de Madrid (Biochemistry), 1993
- PhD Molecular biology with an academic mention by the Education Ministry. Autonomía University Madrid, 1998

Current position

Co-Director, Bone and Joint and Bone Research Unit. Rheumatology Department. Institute Biomedical Research Fundación Jiménez Díaz-Autonomía University. Madrid, since 2020
Associate professor Faculty of Medicine, Autonomía University Madrid, and Nursery School of the Fundación Jiménez Díaz Hospital, since 2005

Previous positions

2010-2020. Deputy director Bone and Joint and Bone Research Unit. Rheumatology Department. Institute Biomedical Research Fundación Jiménez Díaz-Autonomía University. Stabilization contract through the "Miguel Servet" program, ISCIII Category A.
2000-2010. Post-doctoral Researcher. Bone and Joint and Bone Research Unit. Rheumatology Department. Director: Gabriel Herrero-Beaumont. Institute Biomedical Research Fundación Jiménez Díaz-Autonomía University
2010. Researcher at the Medicine department. Faculty of Medicine. Autonomía University. Madrid. Spain
1993-2000. PhD researcher. Experimental Nephrology Laboratory. Director: Jesús Egido de los Ríos. Fundación Jiménez Díaz University Hospital. Madrid. Spain

Education

Degree: Chemistry- Biochemistry specialist. 1993. Complutense University of Madrid
PhD: Biochemistry and Molecular Biology. 1998. Autonomía University of Madrid.

General quality indicators of scientific production

Google scholar data base: H-index: 43; Citations 6834.

Scopus data base: H-index: 38; Documents: 109; Citations: 4503

In the last 5 years, she has published more than 30 JCI indexed research papers in international journals, 80% of these publications on Q1 and 10% of these publications in D1.

Principal Investigator in different Public Research Projects since 2006, from the ISCIII, National and International companies.

Supervisor of 15 PhD Thesis. Reviewer of several scientific journals in Rheumatology, Guest Editor in Frontiers in Medicine.

Relevant International publications (2017-act)

1. Roman-Blas JA, Castañeda S, Sánchez-Pernaute, **Largo R**, Herrero-Beaumont G, and the CS/GS COMBINED THERAPY Study group. Chondroitin sulfate plus glucosamine sulfate shows no superiority over placebo in a randomized, double-blind, placebo-controlled clinical trial in patients with knee osteoarthritis. **Arthritis Rheumatol.** 69(1):77-85, 2017. doi: 10.1002/art.39819. IMPACT FACTOR 6.918 Q1, D1.
2. Roman-Blas JA, Mediero A, Tardío L, Portal-Núñez S, Gratal P, Herrero-Beaumont G, **Largo R**. Glucosamine hydrochloride plus chondroitin sulfate does not improve joint damage in an experimental model of osteoarthritis in rabbits. **Eur J Pharmacol** 12;794:8-14, 2017. doi: 10.1016/j.ejphar.2016.11.015. IMPACT FACTOR 2.896 Q2.
3. Portal-Núñez S, Mediero A, Esbrit P, Sánchez-Pernaute O, **Largo R***, Herrero-Beaumont, G*. The unexpected bone formation derived from RANKL Blocking by denosumab. ***Authors have equal status. Trends Endocrinol & Metab** 28:695-704, 2017. doi: 10.1016/j.tem.2017.06.003. IMPACT FACTOR 10.893 Q1, D1.
4. Herrero-Beaumont G, **Largo R**. SYSADOA trials, CONCEPT clear, uncertainties unchanged. **Nat Rev Rheum.** 13:576-577, 2017. doi: 10.1038/nrrheum.2017.131. IMPACT FACTOR 12.188 D1, Q1.
5. Little RD, Prieto-Potin I, Perez-Baos S, Villalvilla A, Gratal-Viñuales P, **Largo R**, Herrero-Beaumont G. Compensatory anabolic signaling in the sarcopenia of experimental chronic arthritis. **Sci Rep** 24;7:6311, 2017. doi: 10.1038/s41598-017-06581-6. IMPACT FACTOR 4.259 Q1.
6. Pérez-Baos S, Barrasa JJ, Gratal P, Larrañaga-Vera A, Prieto-Potin I, Herrero-Beaumont, **Largo R**. Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis. **Br J Pharmacol.** 174(18):3018-3031, 2017. doi: 10.1111/bph.13932. IMPACT FACTOR 5.491, Q1 D1.
7. Larrañaga-Vera A, Pérez-Baos S, Lamuedra A, Prieto-Potin I, López-Oliva F, Peña L, Herrero-Beaumont G, **Largo R**. Synovial Lipodystrophy induced by Hypercholesterolemia aggravates synovitis in an experimental model of osteoarthritis in rabbits. **Arthritis Res Ther.** 1;19:264, 2017. doi: 10.1186/s13075-017-1473-z. IMPACT FACTOR 4.269 Q1.
8. Naredo E, Medina JP, Pérez-Baos S, Herrero-Beaumont G, **Largo R**. Performance and validity of musculoskeletal ultrasound in assessment of synovial inflammation in experimental acute gout. **Ultrasound Med Biol** 44(7):1516-1524, 2018. IMPACT FACTOR 2.205 Q2.
9. Pérez-Baos S, Prieto-Potin I, Román-Blas JA, Sánchez-Pernaute O, **Largo R**, Herrero-Beaumont G. Mediators and Patterns of Muscle Loss in Chronic Systemic Inflammation. **Front Physiol.** 24;9:409, 2018. IMPACT FACTOR 3.201, Q2
10. Varela-Eirín M, Varela-Vázquez A, Guitián-Caamaño A, Paíno CL, Mato V, **Largo R**, Aasen T, Tabernero A, Fonseca E, Kandouz M, Caeiro JR, Blanco A, Mayán MD. Targeting of chondrocyte plasticity via connexin43 modulation attenuates cellular senescence and fosters a pro-regenerative environment in osteoarthritis. **Cell Death Dis.** 5;9(12):1166, 2018. IMPACT FACTOR 5.959, Q1
11. Estañ MC, Fernandez-Núñez E, Zaki MS, Esteban MI, Donkervoort S, Hawkins C, Caparros-Martin JA, Saade DD, Nevado J, Lamuedra A, **Largo R**, Herrero-Beaumont G, Regadera J, Hernandez-Chico C, Tizzano EF, Martinez-Glez V, Carvajal JJ, Zong R, Nelson D, Otaify GA,

- Temtamy S, Aglan M, Issa M, Bönnemann CG, Lapunzina P, Yoon G, Ruiz-Perez VL. Recessive mutations in muscle-specific isoforms of FXR1 cause 2 congenital multi-minicore myopathy. **Nat Commun** 15;10(1):797, 2019. IMPACT FACTOR 11.878, D1
12. Conesa FM, Llamas-Granda P, Larrañaga-Vera A, Wilder T, **Largo R**, Herrero-Beaumont G, Cronstein B, Mediero A. Tenofovir causes bone loss via decreased bone formation and increased bone resorption, which can be counteracted by dipyrindamole in mice. **J Bone Min Res.** 34(5):923-938, 2019. IMPACT FACTOR 6.314, Q1
 13. Herrero-Beaumont, G, Pérez-Baos, S, Sánchez-Pernaute, O, Roman-Blas JA, Lamuedra, A, **Largo R**. Targeting Chronic Innate Inflammatory Pathways, the Main Road to Prevention of Osteoarthritis Progression. **Biochem Pharmacol** 165:24-32, 2019. IMPACT FACTOR 4.825, Q1 D1.
 14. Gratal P, Mediero A, Sánchez-Pernaute O, Prieto-Potin I, Lamuedra A, Perez-Ruiz VL, Herrero-Beaumont G, **Largo R**. Chondrocyte enlargement is a 1 marker of osteoarthritis severity. **Osteoarthritis Cartil** 27(8):1229-1234, 2019. IMPACT FACTOR 4.879, Q1 D1.
 15. Herrero-Beaumont G, Roman-Blas JA, Mediero A, Sánchez-Pernaute O, **Largo R**. Treating Osteoporotic Osteoarthritis or the Art of Cutting a Balding Man's Hair. **Osteoarthritis Cartil** 28:239-241, 2020. IMPACT FACTOR 4.879, Q1 D1.
 16. Roman-Blas JA, Mendoza-Torres L, Sánchez Pernaute O, **Largo R**, Herrero-Beaumont G. Setting up distinctive outcome measures for each OA Phenotype. **Ther Adv Musc Dis** 10;12, 2020. IMPACT FACTOR 5.346, Q1. doi: 10.1177/1759720X20937966.
 17. Lamuedra A, Gratal P, Calatrava L, Ruiz-Perez VL, **Largo R**, Herrero-Beaumont G. Disorganization of Chondrocyte Columns in the Growth Plate does not Aggravate Experimental Osteoarthritis in Mice. **Sci Rep.** 1;10:10745. doi: 10.1038/s41598-020-67518-0, 2020. IMPACT FACTOR 4.379, Q1.
 18. Villalvilla A, Larrañaga-Vera A, Lamuedra A, Perez-Baos S, López-Reyes AG, Herrero-Beaumont G, **Largo R**. Modulation of the inflammatory process by hypercholesterolemia in Osteoarthritis. **Front Med.** (Lausanne). 2020 Sep 25;7:566250. doi: 10.3389/fmed.2020.5662502020. IMPACT FACTOR 5.091, Q1.
 19. Gratal P, Lamuedra A, Medina JP, Bermejo-Álvarez I, **Largo R**, Herrero-Beaumont G, Mediero A. Purinergic system signaling in metainflammation-associated Osteoarthritis. **Front. Med** (Lausanne). 7:506, 2020. doi: 10.3389/fmed.2020.00506 IMPACT FACTOR 5.091, Q1.
 20. Herrero-Beaumont G, **Largo R**. Glucosamine and O-GlcNAcylation: A novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation? **Ann Rheum Dis** 79(10):1261-63, 2020. doi: 10.1136/annrheumdis-2020-2174542020. IMPACT FACTOR 19.103, Q1 D1.
 21. Filippou G, Scanu A, Adinolfi A, Toscano C, Gambera D, **Largo R**, Naredo E, Calvo E, Herrero-Beaumont G, Zufferey P, Madelaine Bonjour C, MacCarter DK, Makman S, Weber Z, Figus F, Möller I, Gutierrez M, Pineda C, Clavijo Cornejo D, Garcia H, Ilizaliturri V, Mendoza Torres J, Pichardo R, Rodriguez Delgado LC, Filippucci E, Cipolletta E, Serban T, Cirstoiu C, Vreju FA, Grecu D, Mouterde G, Govoni M, Punzi L, Damjanov NS, Keen HI, Bruyn GAW, Terslev L, D'Agostino MA, Scirè CA, Iagnocco A. Criterion validity of ultrasound in the identification of calcium pyrophosphate crystal deposits at the knee: an OMERACT ultrasound study. **Ann Rheum Dis** 80(2):261-267, 2021. doi: 10.1136/annrheumdis-2020-217998. IMPACT FACTOR 19.103, Q1 D1.
 22. Mobasher A, Fonseca JE, Gualillo O, Henrotin Y, **Largo R**, Herrero-Beaumont G, Castro Rocha FA. Inflammation and Biomarkers in Osteoarthritis. **Front. Med.** (Lausanne). *Front. Med.*, 27, 2021. doi.org/10.3389/fmed.2021.727700. IMPACT FACTOR 5.091, Q1
 23. **Largo R**, Herrero-Beaumont G. Joint obesity as a pathogenic factor in osteoarthritis. **Osteoarthritis Cartilage** 11:S1063-4584(21)00806-2, 2021. doi: 10.1016/j.joca.2021.05.062. IMPACT FACTOR 6.576, Q1 D1.

24. Najm A, Félicie Costantino, Alivernini S, Alunno A, Bianchi E, Bignall J, Boyce B, Cañete JD, **Largo R**, Carubbi F, Durez P, Fonseca JE, Andreas Just S, Maybury M, Manzo A, Naredo E, Orr C, Pitzalis C, Rivellese F, Romao V, Tas S, van Rompay J, Veale D, D'Agostino MA, Filer A. EULAR Points to consider for minimal reporting requirements in synovial tissue research in rheumatology. **Ann Rheum Dis**. 81(12):1640-1646, 2022 doi: 10.1136/annrheumdis-2021-221875. IMPACT FACTOR 27.973, Q1 D1.
25. Lamuedra A, Gratal P, Calatrava L, Ruiz-Perez VL, Palencia-Campos A, Portal-Núñez S, Mediero A, Herrero-Beaumont G, **Largo R**. Blocking chondrocyte hypertrophy in conditional Evc knockout mice does not modify cartilage damage in osteoarthritis. **FASEB J**. 36:e22258, 2022. doi: 10.1096/fj.202101791RR. IMPACT FACTOR 5.192, Q1.
26. Gratal P, Mediero A, Lamuedra A, Matamoros-Recio A, Herrero-Beaumont G, Martín-Santamaría S, **Largo R**. 6-Shogaol (enexasogol) treatment improves experimental knee osteoarthritis exerting a pleiotropic effect over immune innate signalling responses in chondrocytes. **Br J Pharmacol** 179(22):5089-5108, 2022. doi: 10.1111/bph.15908 doi: IMPACT FACTOR 8.740 Q1 D1.
27. Varela-Eirín M, Carpintero-Fernandez P, Guitián-Caamaño A, Varela-Vázquez A, García-Yuste A, Sanchez-Temprano A, Bravo S, Yáñez Cabanas J, Fonseca E, **Largo R**, Mobasher A, Caeiro JR, Mayan M. Extracellular vesicles enriched in connexin 43 promote a senescent phenotype in bone and synovial cells contributing to osteoarthritis progression. **Cell Death Dis** 5;13(8):681, 2022. doi: 10.1038/s41419-022-05089-w. IMPACT FACTOR 9.705 Q1
28. Sirotti S, Becce F, Sconfienza LM, Terslev L, Naredo N, Zufferey P, Pineda C, Gutierrez M, Adinolfi A, Serban T, MacCarter D, Mouterde G, Zanetti A, Scanu A, Möller I, Novo-Rivas U, **Largo R**, Sarzi-Puttini P, Abhishek A, Choi HK, Dalbeth N, Pascart T, Tedeschi SK, D'Agostino MA, Iagnocco AM, Keen HI, Scirè CA, Filippou G. Reliability and diagnostic accuracy of conventional radiography for the diagnosis of CPPD: performance of the novel definitions developed by an international multidisciplinary working group. **Arthritis Rheumatol** 19 Sep 2022, DOI: 10.1002/art.42368. IMPACT FACTOR 15.483 Q1 D1
29. Delgado-Arévalo C, Calvet-Mirabent M, Triguero-Martínez A, Vázquez de Luis E, Benguría-Filippini A, **Largo R**, Calzada-Fraile D, Popova O, Sánchez-Cerrillo I, Tsukalov I, Moreno-Vellisca R, de la Fuente H, Herrero-Beaumont G, Ramiro A, Sánchez-Madrid F, Castañeda S, Dopazo A, González Álvaro I, Martín-Gayo E. NLRC4 -mediated activation of CD1c+ dendritic cells contributes to perpetuation of synovitis in rheumatoid arthritis. **J Clin Invest Insights** 2022 Oct4:e152886. doi: 10.1172/jci.insight.152886. Online ahead of print. IMPACT FACTOR 9.533 Q1